Oxaliplatin plus Capecitabine in the Perioperative Treatment of Locally Advanced Gastric Adenocarcinoma in Combination with D2 Gastrectomy: NEO-CLASSIC Study.
Yiyi YuYong FangZhenbin ShenYan WangMin YanHui CaoYingbin LiuXuefei WangYuehong CuiFenglin LiuWeidong ChenWei LiQian LiHuiqin JiangYihong SunTian-Shu LiuPublished in: The oncologist (2019)
These findings suggest that combination therapy with capecitabine and oxaliplatin as perioperative chemotherapy, followed by D2 gastrectomy, is effective and safe in late-stage, locally advanced gastric cancer. Although enrollment exceeded the 47 patients required to identify an increase in the ORR by 15% (from 40% to 55%), results did not meet the primary endpoint.
Keyphrases
- locally advanced
- combination therapy
- neoadjuvant chemotherapy
- rectal cancer
- squamous cell carcinoma
- phase ii study
- radiation therapy
- end stage renal disease
- cardiac surgery
- patients undergoing
- newly diagnosed
- ejection fraction
- chronic kidney disease
- peritoneal dialysis
- acute kidney injury
- prognostic factors
- clinical trial
- randomized controlled trial
- study protocol
- health insurance